Stock Market News
Two AstraZeneca drugs get EU backing for treatment of some breast cancers
2022.06.27 09:55
FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo
(Reuters) – AstraZeneca (NASDAQ:AZN) said on Monday its cancer drugs Lynparza, developed with Merck & Co and Enhertu, developed with Japan’s Daiichi Sankyo, were recommended for the treatment of some high-risk breast cancers in the European Union.